Vagus nerve stimulation (VNS) for epilepsy is not experimental. The FDA approved it in 1997 for drug-resistant epilepsy, making it one of the longest-established neuromodulation therapies in medicine. Nearly three decades of clinical data show that it reduces seizure frequency in roughly half of patients who receive it — and unlike many epilepsy medications, its effectiveness tends to improve over years rather than declining. Here’s how it works, what the devices do, and what the evidence actually shows.

Why the Vagus Nerve Affects Seizures

Seizures are episodes of abnormal, synchronized electrical activity in the brain. The vagus nerve provides a pathway to modulate that activity without opening the skull. Surgeons implant the electrode on the left cervical vagus nerve specifically — the right vagus carries more cardiac innervation, and stimulating it poses greater risk of heart rhythm disturbances.

Electrical pulses travel up the vagus nerve’s afferent fibers to the nucleus tractus solitarius (NTS) in the brainstem. From there, signals project to the locus coeruleus, which releases norepinephrine widely across the cortex. Norepinephrine raises the seizure threshold by stabilizing neuronal membranes and reducing the synchronized firing that produces seizures. The NTS also projects to the dorsal raphe nucleus, releasing serotonin — another neurotransmitter with anti-seizure properties. Additionally, VNS appears to enhance GABAergic (inhibitory) signaling in the thalamus and cortex.

The full mechanism isn’t completely understood, which is common in neuromodulation. What matters clinically is that the outcomes are well documented even when the mechanism remains partially opaque.

The Device and Surgery

A VNS system has two components: a pulse generator about the size of a silver dollar, implanted under the skin in the left upper chest, and a thin lead wire that wraps around the left cervical vagus nerve in the neck. Implantation is typically an outpatient procedure lasting about an hour under general anesthesia, with two small incisions — one in the chest and one in the neck.

The device is programmed to deliver brief electrical pulses at regular intervals, typically 30 seconds of stimulation every five minutes, though parameters are adjusted for each patient. Most people feel a mild tingling or vibration in the throat during stimulation but adapt quickly. Patients also receive a handheld magnet they can swipe over the generator to trigger an extra burst of stimulation when they feel a seizure starting — a feature many patients consider the most empowering aspect of the therapy.

Battery life ranges from three to eight years depending on stimulation settings. Replacement requires only a brief chest procedure; the lead on the nerve stays in place.

Current Devices

LivaNova (formerly Cyberonics), based in London, is the only manufacturer of FDA-approved implantable VNS systems for epilepsy. The technology has evolved through several generations. The AspireSR, approved in 2015, was the first model with AutoStim — automatic seizure detection based on ictal tachycardia (the heart rate increase that accompanies many seizures). When the device detects a rapid heart rate spike matching seizure patterns, it delivers stimulation without the patient needing to use the magnet. This matters because many seizures impair consciousness, making voluntary magnet use impossible.

The SenTiva, approved in 2017, added a smaller profile, day-and-night programming (different settings for sleep versus waking hours), and scheduled dose adjustments that automatically titrate stimulation parameters over time. These features reduce the number of programming visits needed.

The trajectory of development is toward more responsive, closed-loop systems — devices that continuously monitor physiological signals and adjust stimulation in real time rather than delivering pulses on a fixed schedule.

What the Evidence Shows

VNS is indicated for drug-resistant epilepsy, defined as failure to achieve seizure control with two or more appropriately chosen and dosed anti-seizure medications. The pivotal clinical trials (E03 and E05) established the therapy, and decades of post-market data have refined expectations.

The pattern that distinguishes VNS from many other therapies is progressive improvement. At three months post-implantation, roughly 25 to 30 percent of patients are “responders” (50 percent or greater seizure reduction). At one year, the responder rate climbs to approximately 35 to 40 percent. By two years, it reaches roughly 50 percent. Some registry data suggest continued improvement out to five years and beyond. This progressive effect is thought to reflect gradual neuroplastic changes in the brainstem circuits being stimulated.

Complete seizure freedom is less common — roughly five to eight percent at two years — and VNS is best understood as adjunctive therapy rather than a standalone cure. Most patients continue anti-seizure medications, though some achieve enough improvement to reduce medication doses. Beyond seizure reduction, patients frequently report improved mood, alertness, and quality of life, which may partly explain why the FDA also approved VNS for treatment-resistant depression in 2005.

Side Effects and Limitations

The most common side effect is voice alteration — hoarseness or a change in vocal quality during stimulation periods, affecting 60 to 70 percent of patients. This occurs because the stimulation activates the recurrent laryngeal nerve (a branch of the vagus), which controls the vocal cord muscles. Most patients find it tolerable and report that it diminishes over months. Other stimulation-related effects include throat tingling, cough, and mild shortness of breath during the “on” periods.

Surgical risks are low but include infection at the implant site (two to three percent), temporary vocal cord paralysis, and rare lead-related complications. The surgery avoids the brain entirely, which gives VNS a safety advantage over intracranial procedures.

VNS doesn’t work for everyone. Approximately 25 to 30 percent of patients see minimal benefit. There are currently no reliable pre-implantation predictors of who will respond, though research into biomarkers is ongoing.

VNS Compared to Other Neuromodulation

VNS isn’t the only neuromodulation option for epilepsy. Responsive neurostimulation (RNS), manufactured by NeuroPace, involves electrodes placed directly on or within the brain at identified seizure foci. It detects abnormal electrical activity and delivers targeted stimulation to disrupt seizures in real time. RNS requires craniotomy and precise localization of seizure origin, but offers the advantage of treating the source directly.

Deep brain stimulation (DBS) targeting the anterior nucleus of the thalamus received FDA approval for epilepsy in 2018. Like RNS, it requires intracranial electrode placement. Transcutaneous vagus nerve stimulation (tVNS), which stimulates the auricular branch of the vagus through the ear, is non-invasive and has some evidence for epilepsy but is not FDA-approved for seizures and produces weaker effects than implanted VNS.

The choice among these options depends on seizure type, whether a focal origin can be identified, surgical candidacy, and patient preference. VNS remains the most common first-line neuromodulation for drug-resistant epilepsy because of its extracranial approach, established long-term safety data, and the well-documented pattern of improving efficacy over time.

Want to understand the full picture of how vagus nerve stimulation works — for epilepsy, mood, inflammation, and beyond? Get My Vagus Nerve & Me eBook for a comprehensive look at the nerve powering these breakthroughs.

Keep reading

Vagus Nerve Entrapment Syndromes6 min read

Understanding the Symptoms of Vagus Nerve Injury13 min read

Understanding Refractory Epilepsy: Causes, Symptoms, and Treatment8 min read